Tests on kids suffering from cerebral palsy or mental disabilities in Punjab have disclosed high levels of uranium.
A charity based in the Punjab’s Faridkot city said chemical analyses of hair samples collected from 149 children in its care showed "unpredicted quantities" of toxicants.
The kids who took part in the study were below the age of 13 years, it said.
The outcome has puzzled the functionaries as there are no known sources of uranium in Punjab.
A decade-long research conducted by the Tata Memorial Hospital, and backed by the Bill & Melinda Gates Foundation, has reached a noteworthy conclusion with regard to detection of cervical cancer.
According to the study, genetic testing for human papilloma virus or HPV - by collecting DNA cells from the cervix - was a better method for detecting cervical cancer in comparison to the widely popular method called 'pap smear,' in which cells are collected from the surface of the cervix.
Recent study revealed an association in germs in mouths and increased risk of heart disease. This study gave the clear indication that oral hygiene has effect on cardio-vascular health.
Researchers at the University at Buffalo analyzed data collected from 386 men and women (35 to 69 years of age) who had suffered a heart attack and
Elan Corp., Plc. and Wyeth decided to stop the ongoing clinical trails testing effect of 2.0 mg/kg dose of experimental Alzheimer's drug bapineuzumab.
Officials from both companies declared the discontinuation of the highest of the three dosing regimens, 2.0 mg/kg, in the two ongoing Phase 3 studies of bapineuzumab in patients with mild-to-moderate Alzheimer's disease, or AD, who do not carry the Apolipoprotein E4, or ApoE4, allele. However testing of the 0.5 mg/kg and 1.0 mg/kg doses in two Phase III trials will continue as planned.
Pfizer Inc (PFE. N) stopped a late-stage study of its drug Sutent. This study was evaluating effect of this drug on advanced breast cancer patients. Sutent is presently approved to treat kidney cancer and a type of gastrointestinal cancer. Company officials notified that three other Phase III trials and two mid-stage trials of Sutent are under way in advanced forms of the cancer.
Researchers were analyzing whether patients taking Sutent could survive longer than patients receiving Xeloda.